BR112023023777A2 - Anticorpos isolados, composição farmacêutica, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, método para produzir um anticorpo, método para tratar uma condição associada à perda de função de trem2, método para reduzir os níveis de strem2 e uso de um anticorpo - Google Patents
Anticorpos isolados, composição farmacêutica, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, método para produzir um anticorpo, método para tratar uma condição associada à perda de função de trem2, método para reduzir os níveis de strem2 e uso de um anticorpoInfo
- Publication number
- BR112023023777A2 BR112023023777A2 BR112023023777A BR112023023777A BR112023023777A2 BR 112023023777 A2 BR112023023777 A2 BR 112023023777A2 BR 112023023777 A BR112023023777 A BR 112023023777A BR 112023023777 A BR112023023777 A BR 112023023777A BR 112023023777 A2 BR112023023777 A2 BR 112023023777A2
- Authority
- BR
- Brazil
- Prior art keywords
- isolated
- trem2
- antibodies
- antibody
- human
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 title 1
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000000556 agonist Substances 0.000 abstract 2
- 238000003776 cleavage reaction Methods 0.000 abstract 2
- 210000000274 microglia Anatomy 0.000 abstract 2
- 230000002025 microglial effect Effects 0.000 abstract 2
- 230000007017 scission Effects 0.000 abstract 2
- 230000007351 Aβ plaque formation Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 238000005056 compaction Methods 0.000 abstract 1
- 238000010494 dissociation reaction Methods 0.000 abstract 1
- 230000005593 dissociations Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000010172 mouse model Methods 0.000 abstract 1
- 210000000066 myeloid cell Anatomy 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
anticorpos isolados, composição farmacêutica, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, método para produzir um anticorpo, método para tratar uma condição associada à perda de função de trem2, método para reduzir os níveis de strem2 e uso de um anticorpo. este pedido divulga, inter alia, certos anticorpos que se ligam especificamente ao trem2 humano (receptor desencadeador expresso em células mieloides 2). em algumas realizações, os anticorpos atuam como agonistas de trem2. em algumas realizações, os anticorpos no presente documento se ligam especificamente à região de haste de trem2 humano intacto, sem ligação ao trem2 solúvel, que é o produto da clivagem do trem2 entre os resíduos h157 e s158. em algumas realizações, os anticorpos atuam como agonistas de trem2, ligam-se especificamente à região de haste de trem2 com constantes de dissociação variando de 10 nm a tão baixas quanto 100-500 pm, 10-50 pm ou 1-10 pm, ligam-se especificamente a um trem2 epítopo abrangendo o sítio de clivagem h157-s158 e não se liga ao trem2 solúvel. em algumas realizações, os anticorpos no presente documento também inibem a liberação de trem2 solúvel em um modelo de célula da micróglia humana e in vivo em um modelo de camundongo, diminuem os níveis de trem2 solúvel no plasma, csf e/ou cérebro, aumentam a sobrevida das células da micróglia humana e aumentam a formação e compactação da placa aß em um modelo de micróglia humana (por exemplo, conforme medido pela intensidade aumentada da placa aß e/ou intensidade aumentada da placa x04 na micróglia humana) e, assim, pode fornecer uma série de atividades neuroprotetoras.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163188800P | 2021-05-14 | 2021-05-14 | |
PCT/US2022/028920 WO2022241082A1 (en) | 2021-05-14 | 2022-05-12 | Agonists of trem2 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023023777A2 true BR112023023777A2 (pt) | 2024-01-30 |
Family
ID=81851381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023023777A BR112023023777A2 (pt) | 2021-05-14 | 2022-05-12 | Anticorpos isolados, composição farmacêutica, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, método para produzir um anticorpo, método para tratar uma condição associada à perda de função de trem2, método para reduzir os níveis de strem2 e uso de um anticorpo |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220389097A1 (pt) |
EP (1) | EP4337317A1 (pt) |
JP (1) | JP2024518545A (pt) |
KR (1) | KR20240007928A (pt) |
CN (1) | CN117396510A (pt) |
AR (1) | AR125855A1 (pt) |
AU (1) | AU2022273303A1 (pt) |
BR (1) | BR112023023777A2 (pt) |
CA (1) | CA3219425A1 (pt) |
TW (1) | TW202306993A (pt) |
WO (1) | WO2022241082A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019022752A2 (pt) * | 2017-08-03 | 2020-05-19 | Alector Llc | anticorpos anti-trem2 e métodos de uso dos mesmos |
WO2023164516A1 (en) | 2022-02-23 | 2023-08-31 | Alector Llc | Methods of use of anti-trem2 antibodies |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
CA2293829C (en) | 1997-06-24 | 2011-06-14 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
CA2348292A1 (en) | 1998-10-30 | 2000-05-11 | Takeda Chemical Industries, Ltd. | Betacellulin protein-containing preparation |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
WO2001007611A2 (en) | 1999-07-26 | 2001-02-01 | Genentech, Inc. | Novel polynucleotides and method for the use thereof |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
WO2001025454A2 (en) | 1999-10-04 | 2001-04-12 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
CA2785941C (en) | 2000-10-06 | 2017-01-10 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
CN1555411A (zh) | 2001-08-03 | 2004-12-15 | ���迨�����\���ɷݹ�˾ | 抗体-依赖性细胞毒性增大的抗体糖基化变体 |
EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
JPWO2003085107A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | ゲノムが改変された細胞 |
JP4628679B2 (ja) | 2002-04-09 | 2011-02-09 | 協和発酵キリン株式会社 | Gdp−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞 |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
WO2004024879A2 (en) | 2002-09-16 | 2004-03-25 | Exelixis, Inc. | RORs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
WO2005035586A1 (ja) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | 融合蛋白質組成物 |
EP1705251A4 (en) | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE |
RS55723B1 (sr) | 2003-11-05 | 2017-07-31 | Roche Glycart Ag | Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
RU2386638C2 (ru) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
KR20180068999A (ko) | 2015-10-06 | 2018-06-22 | 알렉터 엘엘씨 | 항-trem2 항체 및 그의 사용방법 |
EP3487886A2 (en) | 2016-07-22 | 2019-05-29 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) | Trem2 cleavage modulators and uses thereof |
BR112019022752A2 (pt) | 2017-08-03 | 2020-05-19 | Alector Llc | anticorpos anti-trem2 e métodos de uso dos mesmos |
CN111448212A (zh) | 2017-09-14 | 2020-07-24 | 戴纳立制药公司 | 抗trem2抗体及其使用方法 |
UY38407A (es) * | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
MA55025A (fr) * | 2019-02-20 | 2021-12-29 | Denali Therapeutics Inc | Anticorps anti-trem2 et leurs procédés d'utilisation |
-
2022
- 2022-05-12 BR BR112023023777A patent/BR112023023777A2/pt unknown
- 2022-05-12 CA CA3219425A patent/CA3219425A1/en active Pending
- 2022-05-12 TW TW111117846A patent/TW202306993A/zh unknown
- 2022-05-12 WO PCT/US2022/028920 patent/WO2022241082A1/en active Application Filing
- 2022-05-12 AR ARP220101265A patent/AR125855A1/es unknown
- 2022-05-12 US US17/742,686 patent/US20220389097A1/en active Pending
- 2022-05-12 KR KR1020237042889A patent/KR20240007928A/ko unknown
- 2022-05-12 CN CN202280034832.8A patent/CN117396510A/zh active Pending
- 2022-05-12 EP EP22726361.3A patent/EP4337317A1/en active Pending
- 2022-05-12 JP JP2023570146A patent/JP2024518545A/ja active Pending
- 2022-05-12 AU AU2022273303A patent/AU2022273303A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4337317A1 (en) | 2024-03-20 |
WO2022241082A1 (en) | 2022-11-17 |
US20220389097A1 (en) | 2022-12-08 |
JP2024518545A (ja) | 2024-05-01 |
KR20240007928A (ko) | 2024-01-17 |
AU2022273303A1 (en) | 2023-11-02 |
CA3219425A1 (en) | 2022-11-17 |
TW202306993A (zh) | 2023-02-16 |
AR125855A1 (es) | 2023-08-16 |
CN117396510A (zh) | 2024-01-12 |
AU2022273303A9 (en) | 2023-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023023777A2 (pt) | Anticorpos isolados, composição farmacêutica, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, método para produzir um anticorpo, método para tratar uma condição associada à perda de função de trem2, método para reduzir os níveis de strem2 e uso de um anticorpo | |
BR112021021156A2 (pt) | Terapêuticos anticorpos totalmente humanos pós-tradução modificados | |
BR112016022819A2 (pt) | uso de um método, método para a produção de um anticorpo com reatividade cruzada para humano e cinomolgo e anticorpo com reatividade cruzada para humano e cinomolgo | |
Colia et al. | Medical treatment of advanced chordomas | |
US20230322878A1 (en) | Compounds for inducing tissue formation and uses thereof | |
BR112013030958A2 (pt) | "anticorpo que se liga ao fator de transformação de crescimento beta e seu uso no tratamento de câncer, fibrose e doenças associadas com expressão do referido fator, bem como molécula de ácido nucleico, vetor de expressão, célula hospedeira e seu método de uso para produzir anticorpo e composição farmacêutica". | |
BRPI0518761A2 (pt) | fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente | |
BR112016030774A2 (pt) | anticorpo ou fragmento de ligação a antígeno do mesmo, uso de um anticorpo, métodos para redução da quantidade de protofibrilas de ?? em um indivíduo, para tratamento e/ou para profilaxia de uma doença, para medição da quantidade de protofibrilas de ?? e/ou de proteína ?? agregada em uma pessoa, e para diagnóstico de uma doença, e, composição farmacêutica | |
BR112015022650A2 (pt) | inibidores de cinase induzível por sal macrocíclico | |
BR112021008774A2 (pt) | Formulação farmacêutica, agente de ligação, métodos para tratamento de uma doença, para produzir uma formulação farmacêutica, para induzir a morte celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, uso de uma formulação farmacêutica | |
Kondo | Autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma | |
PH12020550598A1 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
BR112018067969A2 (pt) | uso de células estaminais de polpa dentária que expressam marcadores neuronais mesenquimais e composições das mesmas para tratar doença neurológica | |
BR112022001359A2 (pt) | Método e composição para anticorpos anti-cd73 e variantes | |
BR112021026789A2 (pt) | Sialidases humanas recombinantes, proteínas de fusão de sialidase e métodos de uso das mesmas | |
Kakkos et al. | Robot-assisted surgery for women with endometrial cancer: Surgical and oncologic outcomes within a Belgium gynaecological oncology group cohort | |
BR112022003762A2 (pt) | Proteínas de fusão terapêuticas | |
BR112016016356A2 (pt) | Imunoterapia baseada em lipossomas | |
BR112015005467A2 (pt) | métodos de tratar condições relacionadas ao cabelo | |
EP3906932A2 (en) | Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof | |
IL299624A (en) | A pharmaceutical composition containing a growth receptor agonist and an adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and its uses | |
BR112016011727A2 (pt) | Antagonistas de gastrina para o tratamento e prevenção de osteoporose | |
JP2019502674A (ja) | 組織形成誘導用化合物及びその使用 | |
BR112019004504A2 (pt) | anticorpo monoclonal ou fragmento de ligação do mesmo, molécula, vetor, célula, método para produzir um anticorpo ou fragmento de ligação, composição, e, uso da composição | |
BR112021019571A2 (pt) | Receptor quimérico que reconhece o sítio de modificação do anticorpo |